CIPROFLOXACIN HYDROCHLORIDE Drug Patent Profile

Which patents cover Ciprofloxacin Hydrochloride, and what generic alternatives are available?

Ciprofloxacin Hydrochloride is a drug marketed by Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Pharmobedient, Rising, Rubicon Research, The J Molner, Watson Labs Inc, New Heightsrx, Aiping Pharm Inc, Amneal, Aurobindo Pharma, Barr, Carlsbad, Chartwell, Dr Reddys Labs Ltd, Hikma, Ivax Sub Teva Pharms, Natco, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique, Watson Labs, Yiling, and Cosette Pharms Nc. and is included in twenty-nine NDAs.

The generic ingredient in CIPROFLOXACIN HYDROCHLORIDE is ciprofloxacin hydrochloride; hydrocortisone. There are thirty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride; hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ciprofloxacin Hydrochloride

A generic version of CIPROFLOXACIN HYDROCHLORIDE was approved as ciprofloxacin hydrochloride; hydrocortisone by COSETTE PHARMS NC on November 10^th, 2025.

Summary for CIPROFLOXACIN HYDROCHLORIDE

US Patents:	0
Applicants:	28
NDAs:	29
Finished Product Suppliers / Packagers:	54
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	327
Patent Applications:	4,032
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIPROFLOXACIN HYDROCHLORIDE
What excipients (inactive ingredients) are in CIPROFLOXACIN HYDROCHLORIDE?	CIPROFLOXACIN HYDROCHLORIDE excipients list
DailyMed Link:	CIPROFLOXACIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Faiz ur rahman	NA
Stanford University	EARLY_PHASE1
Uppsala University	PHASE4

See all CIPROFLOXACIN HYDROCHLORIDE clinical trials

Pharmacology for CIPROFLOXACIN HYDROCHLORIDE

Drug Class	Fluoroquinolone Antibacterial Quinolone Antimicrobial
Mechanism of Action	Cytochrome P450 1A2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for CIPROFLOXACIN HYDROCHLORIDE

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for CIPROFLOXACIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nostrum Labs	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076138-002	Jun 9, 2004		DISCN	No	No
Hikma	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076558-003	Jun 9, 2004	AB	RX	No	No
Sun Pharm Inds Ltd	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	075747-001	Jun 9, 2004		DISCN	No	No
Unique	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076639-003	Sep 10, 2004	AB	RX	No	No
Pliva	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076426-004	Jun 15, 2005		DISCN	No	No
Sun Pharm Inds Ltd	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	075747-002	Jun 9, 2004		DISCN	No	No
Teva	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076136-001	Jun 9, 2004		DISCN	No	No

Market Dynamics and Financial Trajectory for Ciprofloxacin Hydrochloride

Last updated: February 8, 2026

Market Size and Growth Trends

Ciprofloxacin hydrochloride is a broad-spectrum fluoroquinolone antibiotic primarily used to treat bacterial infections such as urinary tract infections, respiratory tract infections, and gastrointestinal infections. The global antibiotic market was valued at approximately $55 billion in 2022, with fluoroquinolones accounting for a significant portion. Ciprofloxacin held a dominant share historically, driven by its potency, convenience, and widespread approval.

Between 2018 and 2022, the ciprofloxacin segment demonstrated an estimated compound annual growth rate (CAGR) of 2.6%, attributable to its ongoing prescription in both developed and emerging markets. Regulatory shifts, increased antibiotic resistance, and evolving medical guidelines influence future growth rates, which analysts project to slow slightly to a CAGR of around 1.8% from 2023 to 2030.

Market Drivers

• High Clinical Adoption: Ciprofloxacin's efficacy against gram-negative bacteria sustains its prescription volume. It is included in treatment guidelines across multiple infection types.
• Patent Expiry and Generics: The original patents expired in the early 2000s. The market is now dominated by generic manufacturers, which has decreased prices and increased accessibility.
• Increasing Antibiotic Resistance: Growing resistance could lead to expanded use in resistant cases but may also prompt shifts toward newer antibiotics, constraining Ciprofloxacin's market share.
• Regulatory and Safety Concerns: FDA warnings in 2016 about severe side effects have impacted prescribing habits, leading to reduced use in some markets.

Market Constraints

• Regulatory Restrictions: Some countries impose restrictions on fluoroquinolone prescriptions, limiting Ciprofloxacin's growth.
• Antibiotic Stewardship Programs: Increased focus on antibiotic resistance has promoted more judicious use, impacting sales volumes.
• Rise of Alternatives: Development of novel classes like fosfomycin and biotherapeutics limits potential growth.

Competitive Landscape

Ciprofloxacin faces competition from newer antibiotics such as levofloxacin and moxifloxacin. Generic manufacturers dominate production, with Pfizer, Teva, and Sandoz being prominent players. Entry barriers are low post-patent expiration, leading to intense price competition.

Financial Trajectory

• Revenue Trends: The market revenue for ciprofloxacin was approximately $1.2 billion in 2022. Sales have plateaued or slightly declined over recent years due to safety concerns and prescribing restrictions.
• Pricing Dynamics: Pricing has declined by an average of 4% annually since 2018 globally, with higher reductions in mature markets like North America and Europe. Emerging markets see more stable pricing due to less regulation.
• Profitability: High-margin sales have diminished with increased generic competition, reducing margins for manufacturers. Companies have shifted focus to volume sales rather than per-unit profit.

Future Outlook

Forecasts suggest a modest decline in global Ciprofloxacin revenue, averaging a 1.2% annual decrease from 2023 through 2030. However, it remains vital in specific therapeutic areas, especially in areas with limited access to newer antibiotics. Innovation, such as formulations with improved safety profiles, may stabilize or restore revenue margins.

Key Factors Affecting Future Financial Performance

• Regulatory status: Widespread restrictions or bans would negatively impact sales.
• Emergence of resistance: Increased resistance could either expand use in resistant infections or shift treatment paradigms towards alternative drugs.
• Generic market dynamics: Price reductions and manufacturer competition will continue to exert downward pressure on revenues.
• Market expansion in emerging economies: Growing healthcare infrastructure might sustain or slightly increase use, offsetting declines in mature markets.

---

Key Takeaways

• Ciprofloxacin hydrochloride's market has stabilized with slight decline prospects, dominated by generic suppliers.
• Market growth is constrained by safety concerns, regulatory restrictions, and antibiotic resistance.
• Revenue is declining due to price erosion and shrinking prescription volumes, projected to continue through 2030.
• Development of alternatives and stewardship measures will further influence market dynamics.
• Companies should leverage formulations or indications that target resistant infections to sustain profitability.

---

FAQs

1. How is antibiotic resistance affecting Ciprofloxacin sales?
Resistance reduces ciprofloxacin's effectiveness against certain bacteria, shrinking its use in treating resistant cases. While resistance can prompt increased use of Ciprofloxacin in some resistant infections, stewardship guidelines often restrict its use, leading to overall sales declines.

2. What regulatory trends could impact Ciprofloxacin markets?
The FDA and EMEA have issued warnings and restrictions; further restrictions are possible in countries with rising resistance or safety concerns, potentially reducing prescription volumes.

3. Are there emerging markets opportunities for Ciprofloxacin?
Yes. Countries with expanding healthcare infrastructure and limited access to newer antibiotics could sustain or grow Ciprofloxacin demand. However, pricing and regulatory hurdles may influence viability.

4. How do generic manufacturers influence market prices?
Intense competition among generics leads to significant price reductions. Average global price declines of 4% annually are typical, compressing profit margins.

5. What innovations could alter Ciprofloxacin’s market outlook?
Development of formulations with lower side effects, targeted therapies for resistant bacteria, or combination therapies could bolster its value proposition and stabilize revenues.

---

References

1. MarketWatch. "Antibiotics Market Size & Trends." 2023.
2. Research and Markets. "Global Fluoroquinolones Market Report." 2022.
3. U.S. FDA. "Safety Alerts on Fluoroquinolones." 2016.
4. IQVIA. "Global Antibiotics Market Data." 2022.
5. Biopharma Dive. "Impact of Resistance and Regulations on Antibiotics." 2023.